13F Holdings
中文EN

KMDA KAMADA LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY39.7%
TTM EPS YoY40.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—

Margins

Gross margin42.3%
Operating margin14.5%
Net margin11.2%
FCF margin—
EBITDA margin15.4%

Returns

ROE7.6%
ROA5.4%
ROIC (approx.)12.1%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage30.36x

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio-1.4%
Payout ratio114.2%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY2021*2021-12-31
Income statement
Revenue$180.46M$160.95M$142.52M$129.34M$103.64M
Cost of revenue$104.05M$90.99M$87.03M$82.64M$73.31M
Gross profit$76.41M$69.97M$55.49M$46.70M$30.33M
R&D expense$12.99M$15.19M$13.93M$13.17M$11.36M
SG&A expense$18.72M$15.70M$14.38M$12.80M$12.64M
Operating income$26.23M$20.05M$10.06M$4.53M-$696,000
Interest expense$864,000$660,000$1.30M$914,000$283,000
Pretax income$23.47M$13.33M$8.43M-$2.26M-$1.89M
Income tax$3.27M-$1.13M$145,000$62,000$345,000
Net income$20.20M$14.46M$8.28M-$2.32M-$2.23M
EBITDA$27.87M$21.54M$22.78M$16.69M$4.91M
EPS (basic)0.350.250.17-0.05-0.05
EPS (diluted)0.350.250.15-0.05-0.05
Weighted avg. shares (diluted)58.35M57.82M53.68M44.86M44.90M
Balance sheet
Cash & equivalents$75.47M$78.44M$55.64M$34.26M$18.59M
Receivables$27.01M$21.55M$19.88M$27.25M$35.16M
Inventory$84.94M$78.82M$88.48M$68.78M$67.42M
Current assets$193.07M$184.35M$169.96M$139.00M$130.04M
PP&E, netmay include right-of-use assets (IFRS)$41.37M$36.24M$28.22M$26.16M$26.31M
Goodwill$30.31M$30.31M$30.31M$147.01M—
Intangibles——$140.47M$147,072$154.43M
Total assets$378.71M$372.25M$354.91M$322.38M$318.67M
Current liabilities$47.39M$49.39M$49.59M$75.70M$54.06M
Short-term debt$9.92M$10.18M$15.00M$4.44M$2.63M
Long-term debt———$17.41M$20.04M
Total debt———$21.85M$22.67M
Total liabilities$109.64M$112.79M$110.89M$146.36M$141.84M
Shareholders' equity$269.07M$259.46M$244.02M$176.02M$176.82M
Net debt———-$12.41M$4.08M
Shares outstanding57.69M57.51M57.48M44.83M44.80M
Cash flow statement
Operating cash flow$25.49M$47.59M$4.32M$28.59M-$8.82M
Investing cash flow-$9.84M-$10.74M-$5.84M-$3.78M-$61.05M
Financing cash flow-$18.34M-$13.91M$22.68M-$9.34M$18.59M
Depreciation & amortization$1.64M$1.49M$12.71M$12.15M$5.61M
Stock-based compensation$845,000$874,000$1.31M$1.15M$529,000
Dividends paid$11.53M————

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.